Incidence of iris colour change in latanoprost treated eyes

British Journal of Ophthalmology

Volumn 86, Issue 10, 2002, Pages 1085-1088

  Teus, Miguel A ^a,b   Arranz Marquez E ^a   Lucea Suescun, P ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Instituto Oftalmologico de Albacete   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE COLOR; EYE PHOTOGRAPHY; FEMALE; GLAUCOMA; HUMAN; INCIDENCE; MALE; PIGMENT DISORDER; PRIORITY JOURNAL; RISK ASSESSMENT; SLIT LAMP;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; ERYTHROCYTES; EYE COLOR; FEMALE; GLAUCOMA; HUMANS; IRIS; MALE; MIDDLE AGED; PHOTOGRAPHY; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC;

EID: 0036784457     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.86.10.1085     Document Type: Article

References (12)

1. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997;6:430-2.
2. Aim A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-52.
3. Watson P, Stjernschantz J. The Latanoprost study group. A six month, randomized, double masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
4. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41 (Suppl 2):S129-38.
5. Camras CB, Alm A, Watson P, et al. The latanoprost study group. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safely after 1 year of treatment in 198 patients. Ophthalmology 1996;103:1916-24.
6. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7.
7. Camras CB. The United States latanoprost study group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
8. Mastropasqua L, Carpineto P, Ciancaglini M, et al. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550-5.
9. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol 1999;117:394-6.
10. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of irideal melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res 1999;69:431-6
11. Dietrich CE. Zur feinstruktur der Melanocyten der menschlichen Iris. Graefes Arch Klin Exp Ophthalmol 1972;183:317-33.
12. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color. Electron microscopic findings. Arch Ophthalmol 1996;114:443-7.